Bristol-Myers Squibb initiates KarXT trial for adolescent schizophrenia
Bristol-Myers Squibb is conducting a study to evaluate the efficacy and safety of KarXT for treating schizophrenia in adolescents.
Therapeutic Area
Therapeutic area intelligence for Schizophrenia with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.